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Background. Currently, there are no genetic testing guidelines for patients with a primary brain tumor 
(PBT). This population is largely understudied in terms of the family history, tumor grade, pathology, 
and their relation to genetic contribution. Our aim was to describe patient-specific characteristics and 
family histories across mutation-positive, negative, and variant of uncertain significance (VUS) cohorts 
based on cancer-panel genetic test results among patients with a PBT. 
Methods. Subjects were referred for multi-gene panel testing between March 2012 and June 2016. 
Clinical data were ascertained from test requisition forms. The incidence of pathogenic mutations 
(including likely pathogenic) and VUS’s were calculated for each gene and patient cohort.  
Results. Almost all tumors were glial (n=293, 53%) or meningeal pathology (n=222, 40%). Age of 
diagnosis differed significantly between glial and meningeal tumors (p<0.001). Of 654 subjects, panel 
testing identified 104 (16%) individuals with mutations, with 35 (34%) individuals possessing an isolated 
PBT. Genes most frequently yielding a positive result were: CHEK2 (20/104), BRCA2 (13/104), PMS2 
(10/104), TP53 (8/104), and APC (8/104). Of 165 patients with available family history information, 
nearly all (n=157, 95%) reported a family history of some cancer. 
Conclusions. Our data suggest PBTs can be the primary presenting cancer in hereditary syndromes with 
a known PBT risk. While pathology is helpful in narrowing down the differential diagnosis, patients’ 
pathology can be atypical in relation to their hereditary cancer syndrome. Family history evaluations are 
a beneficial risk assessment modality, particularly until testing criteria are developed for PBTs. Further 
research is necessary for the development of genetic testing criteria in the PBT population and more 
robust identification of at-risk individuals.   
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INTRODUCTION.  
The epidemiology of primary brain tumors (PBT), benign or malignant, is poorly understood. 
Aside from high dose ionizing radiation and a hereditary predisposition, there are no proven risk factors 
for PBT development as there are for other cancer types such as breast or colon cancers. The 2016 World 
Health Organization Guidelines classify PBTs according to their histopathology, grade, 
immunohistochemistry, and molecular data. Histopathology of a brain tumor has historically been critical 
for classification; assignment of tumor grade is also based off histopathology(1). These characteristics 
can also be used to develop a differential diagnosis when performing a risk assessment to distinguish 
PBTs that are more likely to have a hereditary etiology.  The major brain tumor predisposition 
syndromes include Li-Fraumeni syndrome (LFS), neurofibromatosis type 1 or 2 (NF1/NF2), von Hippel-
Lindau disease (VHL), tuberous sclerosis complex (TSC), nevoid basal cell carcinoma syndrome 
(NBCCS), constitutional mismatch repair deficiency (CMMRD), Lynch syndrome, and familial 
adenomatous polyposis (FAP).  
One of the first syndromes which identified PBTs as part of their diagnostic criteria was LFS 
which results from a germline mutation in the TP53 gene. PBTs are one of the most common types of 
neoplasm, constituting around 14% of the malignancies seen(2). Additional cancers include soft tissue 
sarcoma, breast cancer, osteosarcoma, and adrenocortical carcinoma. Roughly 60% of the PBTs seen in 
LFS are astrocytomas, with the remaining 40% being medulloblastomas or primitive neuroectodermal 
tumors (PNETs)(2). All patients with choroid plexus carcinoma should be evaluated for LFS.  
NF1 arises from a germline mutation in the NF1 gene,  with around 95% of patients being 
diagnosed by age 8(3). Common features include axillary and inguinal freckling, Lisch nodules, café au-
lait spots, neurofibromas, and optic gliomas. Optic gliomas are low grade pilocytic astrocytomas and are 
seen in about 15% of NF1 patients. Gliomas arising outside of the optic nerve pathway occur in 
approximately 5% of patients(4). Additionally, approximately 50% of NF1 patients develop plexiform 
neurofibromas and 10% develop malignant peripheral nerve sheath tumors(5). 
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NF2 is characterized by the development of bilateral vestibular schwannomas. The causative 
gene is NF2 with the average age of onset spanning from 18-24 years. Almost all individuals present 
with bilateral vestibular schwannomas by 30(6). Additionally, meningiomas are the second most 
common tumor type observed in about half of cases with the lifetime risk approaching 80%(7, 8). They 
are often the primary presenting feature in the pediatric cohort(7) . Two thirds of patients with NF2 will 
develop spinal tumors, including schwannomas, ependymomas or, rarely, astrocytoma. 
VHL carries an increased risk to develop a central nervous system (CNS) malignancy, 
particularly for hemangioblastoma. Hemangioblastomas of the brain or spinal cord are the most common 
tumor type seen in 60-80% of patients, with the average age of diagnosis being 33(9-11). This condition 
is caused by a germline mutation in the VHL gene. Features of VHL include tumors in the CNS, retina, 
kidneys, pancreas, and adrenal glands(10, 12).  
TSC is a genetic condition where individuals develop benign tumors in multiple parts of the 
body such as the skin, lungs, kidneys, and brain. TSC results from a germline mutation in either the 
TSC1 or TSC2 genes. Brain lesions associated with TSC include subependymal nodules (70-80%), 
subependymal giant cell astrocytoma (5-20%), and cortical tubers (70%)(13).  
NBCCS results from a germline mutation in the PTCH1, SUFU, and possibly PTCH2 genes. 
Predominant clinical characteristics include cutaneous findings of basal cell carcinoma, palmoplantar pits 
and epidermoid cysts(14-16). Approximately 5-10% of patients with PTCH1 mutations develop 
medulloblastoma; however, patients with SUFU mutations have an up to 20 times higher risk to develop 
these tumors(17). Patients also have a 5% risk to develop meningiomas(18). They generally present 
within the first two years of life as compared to the general population where age of onset can be 
expected between ages 7-8(14). Often, this malignancy can be the presenting feature of NBCCS. 
CMMRD results from biallelic germline mutations in the mismatch repair, (MMR) genes: 
MLH1, MSH2, MSH6, PMS2. Affected individuals are at increased risk for CNS, hematologic, and 
gastrointestinal malignancies. Bakry et al.(19), found PBTs to be the most common type of malignancy, 
specifically high-grade gliomas, followed by medulloblastoma, and then low-grade glioma. The average 
age of diagnosis for PBTs in CMMRD ranges from 2-11 years of age(19). Currently, the risk to develop 
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a PBT with CMMRD is unknown due to the rarity and the still developing identification protocol of this 
condition, but estimated to be very high(20).  
Similar to CMMRD, recently the predisposition of developing a PBT with Lynch syndrome has 
been further investigated. Lynch syndrome is the most common hereditary, adult-onset form of 
colorectal cancer and caused by a monoallelic germline mutation in one of the MMR genes or EPCAM. 
A study by Therkildsen et al.(21) investigating brain tumors in those with Lynch syndrome found 
glioblastoma was the most common histological subtype followed by astrocytoma and 
oligodendroglioma, with high grade gliomas being more frequent than low grade. Overall, the risk to 
develop a PBT with Lynch syndrome is estimated to be 1-6%, with the higher end of that range being 
attributed to a MSH2 mutation. The average age of diagnosis for a glioma in the general population is 50 
years of age, while the average case of Lynch syndrome is diagnosed in the fourth decade of life.  
FAP results from a germline mutation in the APC gene. Classically, affected individuals present 
with hundreds to thousands of adenomatous colorectal polyps. On average, polyps present around age 
16(22) . Risks for extra colonic cancers include CNS malignancies. Medulloblastoma accounts for 80% 
of PBTs with the remainder including high grade astrocytomas and ependymomas(5). It typically 
presents within the first decade of life with 70% of cases occurring prior to age 16. The lifetime risk of 
developing any PBT in families affected with FAP is seven times higher than the general population 
risk(9). 
As exhibited above, syndromic PBTs are frequently diagnosed at a younger age, with some 
syndromes predisposing to pediatric PBTs. In contrast, the average age of diagnosis in the general 
population is 59 years(23). Early identification of at risk or affected individuals can be valuable in 
prognosis and management recommendations. In patients with CMMRD, it has been shown to be crucial 
in predicting prognosis and allows for earlier tumor resection(20, 24). It also results in screening for 
other associated cancers or prophylactic surgery options. Other benefits include targeted treatment 
options such as avoiding radiation therapy when possible in individuals with LFS(25). Testing at risk 
individuals can result in starting appropriate screening and management as with FAP and LFS. 
Identification of individuals in need of genetic testing or referral to genetic counseling is challenging due 
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to our limited understanding about this population’s landscape.  Perhaps most importantly, there are 
currently no guidelines for genetic testing in patients who present with a PBT.  
Features of genetic testing guidelines for other hereditary cancers include characteristic family 
history, tumor pathology, and age of diagnosis. For example, up to 20% of cases of triple negative 
(estrogen negative, progesterone negative, and HER-2 negative) breast cancer are BRCA positive, 
particularly BRCA1(26). Lynch syndrome colorectal cancers have distinct pathologic features including: 
signet ring cell, mucinous or medullary growth pattern, poor differentiation, and Crohn’s like 
lymphocytic reaction(27, 28). Additionally, with these syndromes, it is understood that a younger age of 
diagnosis and positive family history correlate with an increased risk of a genetic etiology(29-31). Such 
characteristics have not been evaluated in the PBT population.  
One of the first and only studies to examine the contribution of germline mutations toward the 
development of a PBT was by Bergner and Jackson(32). Their analysis focused on individuals with 
positive genetic testing results, revealing that over half the germline mutations identified were in the 
BRCA2, CHEK2, PMS2, and TP53 genes. This suggests the potential for a spectrum of germline 
mutations to be an underlying etiology for the development of a PBT. 
To our knowledge no study has comprehensively examined patient-specific characteristics, such 
as tumor grade, pathology, age at diagnosis, and the presence of other primary cancers, or family history 
information among all individuals undergoing panel testing for a PBT. It is unknown how these 
characteristics may differ across individuals testing positive, negative, or with a VUS. Additionally, 
minimal data exists on the germline genetic testing outcomes for patients with a PBT. It is unclear if 
multi-gene panel genetic testing provides answers for these patients and if so, at what frequency. We 
aimed to help clinicians better identify individuals who should undergo genetic testing. Our aim was to 
investigate how patient-specific characteristics and family history differ across mutation positive, 
negative, and VUS cohorts based on cancer-panel genetic test results among patients diagnosed with a 
PBT.  
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METHODS.  
Participants: 
Consecutive subjects were referred for multi-gene panel testing for a primary brain tumor 
between March 2012 and December 2016 at Ambry Genetics. Panel types ordered included: CancerNext, 
CancerNext Expanded, PancNext, ColoNext, BRCAPlus, PGLNext, GYNPlus, BreastNext, OvaNext, 
CustomNext-Cancer, RenalNext, BRCAPlus Expanded, and BrainTumorNext. The number of genes 
ranged from 6-67. For this retrospective cohort study, all information was de-identified in a secure 
database. This study was conducted in accordance with all regulations set for by the Institutional Review 
Board (IRB) of the University of Texas at Houston Health Sciences Center, Houston, TX and Western 
IRB. Inclusion criteria were a personal history of at least one primary brain tumor. Exclusion criteria 
were a brain tumor as a site of metastasis.  Demographic, clinical history, and family history of cancer 
information were collected from test requisition forms, clinic notes, and pedigrees provided by ordering 
clinicians at the time of testing. Information was collected on current age, personal history, and age at 
diagnosis of other primary cancers, tumor pathology and grade, family history of cancer with cancer 
type, and age at diagnosis among relatives. 
 
 
 
 
 
 
 
 
6 
 
Panel Type Genes (as of December 2016) 
CancerNext 
APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, CDH1, CDK4, 
CDKN2A, CHEK2, DICER1, EPCAM, GREM1 HOXB13, MLH1, 
MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, 
POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, 
TP53 
CancerNext 
Expanded* 
AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, 
CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EPCAM, FANCC, 
FH, FLCN, GREM1, HOXB13, MAX, MEN1, MITF, MLH1, MRE11A, 
MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PHOX2B, PMS2, 
POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, 
RAD51D, RB1, RET, SDHA, SDHB, SDHC, SHDD, SMAD4, SMARCA4, 
SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, 
VHL, XRCC2 
PancNext* 
APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH6, PALB2, 
PMS2, STK11, TP53 
 ColoNext 
APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, 
PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 
PGLNext* 
FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, 
TMEM127, VHL 
BRCAPlus*  BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53 
BRCAPlus-
Expanded* ATM, BRCA1, BRCA2, CDH1, PALB2, PTEN, TP53 
GYNPlus* 
BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, 
PTEN, RAD51C, RAD51D, TP53 
BreastNext 
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, 
MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53 
OvaNext 
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, 
EPCAM, MLH1, MRE11A, MSH2, MSH6,  MUTYH, NBN, NF1, PALB2, 
PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53 
CustomNext-Cancer* 
AIP, ALK, APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, 
CDH1, CDKN1B, CDKN2A, CHEK2, DICER1, EPCAM, FANCC, FH, 
FLCN, GALNT12,GREM1, HOXB13, MAX, MEN1, MET, MITF, MEN1, 
MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, 
PHOX2B, PMS2, POT1, POLD1, POLE, PRKAR1A, PTCH1, PTEN, 
RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, 
SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, 
TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 
RenalNet* 
BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, 
PTEN,  SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL  
BrainTumorNext* 
AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, 
MSH6, NBN, NF1, NF2, PHOX2B, PMS2, POT1, PRKAR1A, PTCH1, 
PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, 
VHL 
 
Table 1. Genetic testing panel types ordered *denotes panels which were not available in March 2012 
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Mutation identification and analysis:  
Genetic testing was completed in Ambry's laboratory using the following protocol. Genomic 
deoxyribonucleic acid was isolated from subject's whole blood or saliva samples using the 
QIAsymphony instrument (Qiagen, Valencia, CA) according to manufacturer's protocols. 
Deoxyribonucleic acid was quantified using a spectrophotometer (Nanodrop, Thermoscientific, 
Pittsburgh, PA or Infinite F200, TECAN, San Jose, CA). Genomic deoxyribonucleic acid was then 
combined with primer pairs in micro-droplets designed to the specified targets for each gene to complete 
sequence enrichment (Raindance Thunderstorm Technologies, Billerica, MA). Using Illumina HiSeq 
technology (Illumina, San Diego, CA) enriched libraries were applied to the solid surface flow cell for 
clonal amplification and sequencing. Sanger sequencing was performed for any region with insufficient 
depth of coverage, defined as 50×. Additionally, bi-directional Sanger sequencing was performed to 
confirm all variant calls, other than known previously defined benign and likely benign alterations. To 
detect large deletions and duplications, a targeted chromosomal microarray with increased probe density 
in regions of interest was completed (Aglient, Santa Clara, CA). 
Initial data processing and base calling, including extraction of cluster intensities, was done 
using RTA 1.12.4 (HiSeq Control Software 1.4.5). Sequence quality filtering was executed with the 
Illumina CASAVA software (ver 1.8.2 Illumina, Hayward, CA). Sequence fragments were aligned to the 
reference human genome (GRCh37) and variant calls were generated using CASAVA. A minimum 
quality threshold of Q30 was applied which translates to an accuracy of >99.9% for called bases and 
mean coverage was >300×. 
Annotated variants were then analyzed to determine the likelihood of pathogenicity and 
classified into five tiers based on the recommendations of the American College of Medical Genetics and 
Genomics(33). Alterations were classified in the following categories: pathogenic mutation, variant 
likely pathogenic, variant of unknown significance (VUS), variant likely benign, and benign based on a 
previously described multifactorial algorithm(34). 
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Data Analysis: 
Data were described using frequencies (with percentages) and medians (with interquartile 
ranges, IQR) for categorical and continuous variables, respectively.  Contingency tests (Chi-square or 
Fisher exact) were used to compare categorical variables across groups. Distribution of continuous 
variables across groups were performed using a Kruskal-Wallis test with a post-hoc Dunn's test.  All 
analyses were performed using STATA (v.13, College Station, TX). Statistical significance was assumed 
at p<0.05. 
Patients were categorized according to pathology and tumor grade for some analyses, as reported 
by the ordering provider. Patients diagnosed with an astrocytoma, oligodendroglioma, oligoastrocytoma, 
ependymoma, optic glioma, glioma, or glioblastoma multiforme (GBMs) were categorized as glial 
tumors. Those with a meningioma were categorized as meningeal. Those with medulloblastoma, 
primitive neuroectodermal tumors (PNETs), or choroid plexus carcinoma were classified as embryonal. 
Those with a hemangioblastoma were classified as mesenchymal. Regarding tumor grade, grade I and II 
glial tumors were categorized as low grade. Juvenile pilocytic astrocytomas were considered to be low 
grade. Grade III and IV glial tumors were categorized as high grade. Glial tumors described as 
“anaplastic” were considered to be grade 3 and GBMs were considered to be grade IV. All meningeal 
tumors were reported to be “benign” and were assumed to be grade I, categorized as low grade. 
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RESULTS.  
Demographics 
A total of 658 patients were selected for this study based upon an initial query of test requisition 
forms of patients identified as having at least one PBT. Four patients were excluded because they did not 
have a diagnosis of a PBT, but an osteoma, epidermoid tumor, cerebellar venous angioma, and dermoid 
tumor. Therefore, a total of 654 patients were included in the final analyses. Seventy-five percent of the 
cohort was female (488/654) and 25% (166/654) male. About two-thirds of the patients were non-
Hispanic white (n=424, 65%). The remaining third of the patients were either Ashkenazi Jewish, (n=54, 
8%), mixed ethnicity (n=41, 6%), African American (n=31, 5%), Hispanic (n=29, 4%), Asian (n=21, 
3%), and Middle Eastern (n=6, 1%). Ethnicity was unknown for 48 patients (8%) (Table 1). 
Demographics Frequency (n, %) 
  
Ethnicity  
    
African 
american/black 31 (5) 
Ashkenazi jewish 54 (8) 
Asian 21 (3) 
Caucasian 424 (65) 
 
Hispanic 29 4) 
Middle eastern 6 (1) 
Mixed ethnicity 41 (6) 
Unknown 48 (7) 
    
Gender  
  
Male 166 (25) 
Female 488 (75) 
  
Total 654 
 
Table 2. Demographics 
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Pathology  
Tumor pathology was available for 558 individuals.  Slightly more than half of all tumors were 
glial (n=293, 53%), with nearly all of the remaining tumors classified as meningeal, (n=222, 40%). Less 
than 10% of the tumors were classified as mesenchymal (n=22, 4%) and embryonal (n=18, 3%). Germ 
cell, nerve sheath tumors, and choroid plexus carcinoma were present in only a single individual for 
each. The distribution of tumor pathology was not significantly different across the positive, negative, 
and VUS genetic testing cohorts. Details about tumor pathology and other patient characteristics can be 
found in Table 2.  
    Glial Meningeal Embryonal Mesenchymal 
    (n= 293) (n= 222) (n= 18) (n= 22) 
            
Age of Diagnosis, years, 
median (IQR)   39 (29 - 51) 50 (43 - 58) 7.5 (6-19) 47.5 (32-56) 
            
Tumor Grade, n (%)           
  1 11 (8) 213 (100) NA 3 (100) 
  2 6 (4) 0 NA 0 
  3 18 (14) 0 NA 0 
  4 98 (74) NA NA NA 
            
Number of primaries, n (%)           
  1 162 (55) 44 (20) 6 (33) 10 (45) 
  2 90 (31) 98 (44) 8 (44) 6 (27) 
  3 30 (10) 57 (26) 3 (17) 5 (23) 
  
4 or 
more 11 (4) 23 (10) 1 (6) 1 (5) 
 
Table 3.  Patient characteristics by pathology type 
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Age at diagnosis  
Age at diagnosis was available for 506 patients. Fifty-seven (11%) were diagnosed under the age 
of 18, 282 (56%) were diagnosed between the ages of 18-50, and 167 (33%) were diagnosed over the age 
of 50. The median age of diagnosis for this cohort was 44 years (STD=17), which is significantly 
younger than the general population, at 59 years (p<0.001).  
Glial (median: 39, IQR: 29-51), meningeal (median: 50, IQR: 43-58), and mesenchymal 
(median: 47.5, IQR: 32-56) tumors were diagnosed in an exclusively adult population. Embryonal 
tumors were diagnosed in a predominantly pediatric population (median: 7.5, IQR: 6-19). This was 
significantly earlier than glial tumors (p<0.001) and meningeal tumors (p<0.001). Glial tumors were 
diagnosed at significantly younger ages than meningeal tumors at (p<0.001). Evaluating age within the 
subtypes of glial tumors, oligodendrogliomas, astrocytomas, and oligoastrocytomas were all diagnosed at 
significantly younger ages compared to glioblastoma multiformes (GBM), (p=0.043, p<0.001, p<0.001, 
respectively). Of note, test result positive astrocytomas were diagnosed at a significantly younger age 
compared to test result negative and VUS astrocytomas (P=0.021). No other significant differences were 
noted between the ages of diagnosis in the positive, negative, and VUS cohorts when compared across 
tumor types.   
Tumor grade  
Of the 354 individuals for whom tumor grade information was available, almost all tumors had 
either glial (137/354, 39%) or meningeal pathology (213/350, 61%). Eighty-six percent of glial tumors 
were high grade (116/138) with 14% being low grade (22/138). Conversely, all meningeal tumors were 
low grade. When comparing high grade and low grade glial tumors, high grade tumors were significantly 
more likely to be diagnosed at an older age (p<0.001). The grade of the glial tumor was not predictive of 
a positive genetic test result in our cohort. Among glial tumors, there was a trend of increasing age of 
diagnosis with increasing tumor grade.  Grade IV tumors (GBMs) were observed in a significantly older 
population (median: 49, IQR: 37-61) compared to grade I (median: 15.5, IQR: 12-35, p <0.001), grade II 
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(median: 18.5, p=0.006) and grade III (median= 32, p<0.001) (Table 3).  There were no statistically 
significant differences in age of diagnosis between grades I, II and III glial tumors.  
 
  Positive VUS Negative 
Tumor Type, n (%)         
  Glial 48 (17) 57 (20) 182 (63) 
  Meningeal 27 (12) 51 (23) 144 (65) 
  Embryonal 3 (17) 7 (39) 8 (44) 
  Mesenchymal 4 (18) 5 (23) 13 (59) 
          
Tumor Grade, n (%) *         
  Low grade 5 (23) 3 (14) 14 (64) 
  High Grade 21 (18) 25 (22) 70 (60) 
 
Table 4. Tumor pathology and grade by genetic testing outcome  
*all meningeal tumors were grade I 
 
 
Number of primaries  
Of the 654 patients, 239 (36%) had one primary cancer (brain tumor), 254 (39%) patients had 2 
primaries, 117 (18%) patients had 3, and 44 (7%) patients had 4 or more. The most common additional 
primary cancers were breast (226/654, 35%), colon (55/654, 8%), and thyroid (36/654, 6%). Individuals 
with multiple primary cancers were significantly more likely to be diagnosed with a PBT at a later age 
compared to those who only had a PBT (p<0.001). Compared to those with a glial tumor, individuals 
with a meningeal tumor were significantly more likely to develop additional primaries (p<0.001). The 
number of additional primary cancers was not predictive of a positive genetic test result.  
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Test results  
One hundred and four of 654 (16%) patients had a positive genetic test result, 141 (21%) with a 
variant of uncertain significance (VUS), and 410 (84%) with negative results. There were 24/141 patients 
who had multiple VUS reported. In the positive testing cohort, five patients were MUTYH carriers and 
five patients had multiple mutations in: APC and ATM, biallelic PMS2 mutations (2), EPCAM and 
MSH2, biallelic TSC1 mutations. The five genes most frequently yielding a positive result were CHEK2 
(20/104, 19%), BRCA2 (13/104, 13%), PMS2 (10/104, 10%), TP53 (8/104, 8%), and APC (8/104, 8%). 
The five genes most frequently yielding a VUS were ATM (17/141, 12%), APC (12/141, 9%), MSH6 
(8/141, 6%), BRCA2 (7/141, 5%), and MLH1 (7/141, 5%).  
Eighty-four of 104 (81%) patients who tested positive had pathology information available. In 
the positive cohort, glial tumors were the most common (50/84, 60%) followed by meningeal tumors 
(27/84, 32%). Astrocytomas made up 42% (21/50) of glial tumors followed by GBM at 34% (17/50). 
The genes most frequently yielding a positive result in glial tumors were CHEK2 (9/50, 18%), PMS2 
(6/50, 12%), TP53 (5/50, 10%). Within glial tumors, astrocytomas returned positive results in APC (2/21, 
10%), CHEK2 (5/21, 24%), PMS2 (4/21, 19%), and TP53 (2/21, 10%). GBM yielded positive results 
most frequently in BRCA1 (2/17, 12%), CHEK2 (2/17, 12%), MUTYH (2/17, 12%), and TP53 (2/17, 
12%). In meningeal tumors, BRCA2 (5/27, 19%) and CHEK2 (6/27, 22%) most frequently yielded a 
positive result. Additional details on pathology and results can be found in Table 4.  
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Tumor 
Type 
(n, %)                             
  Glial 50 3 (6) 2 (4) --- 3 (6) 4 (8) 1 (2) --- 9 (18) 1 (2) 1 (2) --- 3 (6) 
  Meningeal 27 1 (4) 2 (7) 1 (4) --- 1 (4) 1 (4) 1 (4) 6 (22) --- --- 2 (7) --- 
  Embryonal 2 1 (50) --- --- --- --- --- --- --- --- --- --- --- 
  Mesenchymal 4 --- --- --- --- --- --- --- 2 (50) --- --- --- --- 
                              
Glial 
Subsets 
(n, %)                             
  GBM 17 --- 1 (6) --- 1 (6) 1 (6) 1 (6) --- 2 (12) 1 (6) 1 (6) --- 
2 
(12) 
  Astrocytoma 21 2 (10) 1 (5) --- 1 (5) 1 (5) --- --- 5 (24) --- --- --- --- 
  Oligodendroglioma 3 --- --- --- --- --- --- --- 1 (33) --- --- --- --- 
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Table 5. Tumor pathology by genetic testing result  
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Tumor 
Type 
(n, %)                             
  Glial 50 4 (8) --- 6 (12) 2 (4) --- 1 (2) 1 (2) --- --- 7 (14) 1 (2)   
  Meningeal 27 --- 1 (4) 1 (4) --- --- --- 1 (4) 1 (4) 1 (4) --- ---   
  Embryonal 2 --- --- 1 (50) --- --- --- --- --- --- --- --- --- 
  Mesenchymal 4 --- --- --- --- 1 (25) --- --- --- --- --- --- 
1 
(25) 
                              
Glial 
Subsets 
(n, %)                             
  GBM 17 
2 
(12) --- 1 (6) 1 (6) --- --- --- --- --- 2 (12) ---   
  Astrocytoma 21 1 (5) --- 4 (20) 1 (5) --- 1 (5) 1 (5) --- --- 2 (10) 1 (5)   
  Oligodendroglioma 3 --- --- 1 (33) --- --- 1 (33) --- --- --- --- ---   
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Of the 104 patients with a positive test result, 35 (34%) had an isolated PBT with no additional 
primary cancers. These individuals yielded mutations in the genes: APC, ATM, BRCA1, BRCA2, 
CHEK2, MUTYH, NF1, PMS2, POLE, SMARCB1, TP53 and TSC2. Three most common additional 
primaries were breast (26/104, 25%), colon (14/104, 13%), and thyroid (4/104, 4%). Individuals with 
breast cancer as an additional primary possessed mutations in the genes: APC, ATM, BARD1, BRCA1, 
BRCA2, CHEK2, CDKN2A, MSH6, NF1, PALB2, PMS2, and PTEN. Those with colorectal cancer 
possessed mutations in the genes: APC, BRCA1, BRIP1, CHEK2, MLH1, MSH6, MUTYH, PMS2, and 
VHL. Those with thyroid cancer possessed mutations in the genes: APC, ATM, and CHEK2. Additional 
primaries included: melanoma, pancreatic, gastric, prostate, renal, ovarian, sarcoma, leukemia, uterine, 
and other CNS malignancies (Table 5).  
17 
 
 
  
Number 
of 
Positive 
test 
results 
A
P
C
 
A
T
M
 
B
A
P
1
 
B
A
R
D
1
 
B
R
C
A
1
 
B
R
C
A
2
 
B
R
IP
1
 
C
D
K
N
2
A
 
C
H
E
K
2
 
E
P
C
A
M
 
M
L
H
1
 
M
S
H
6
 
  
Additional 
primary 
cancer                             
  Breast 26 2 2 --- --- 1 5 1 1 7 --- --- 1 
  Colon 14 1 --- --- --- 1 --- 1 --- 2 --- 2 1 
  Renal 5 1 --- 1 --- --- --- --- --- 1 --- --- --- 
  Sarcoma 8 --- --- --- --- 1 2 --- --- --- --- --- --- 
  Thyroid 4 1 1 --- --- --- --- --- --- 2 --- --- --- 
  Melanoma 4 --- --- --- --- --- --- --- 1 1 --- 1 --- 
  Ovarian 4 --- --- --- --- --- --- --- 1 --- --- --- --- 
  Pancreatic 3 1 --- --- --- --- --- --- --- 1 1 --- --- 
  Uterine 3 --- --- --- --- --- --- --- --- --- --- --- 1 
  Prostate 2 --- 1 1 --- --- --- --- --- --- --- --- --- 
  CNS 1 --- --- --- --- 1 --- --- --- --- --- --- --- 
  Gastric 1 --- --- --- --- --- --- --- --- --- --- 1 --- 
                              
Isolated 
PBT   35 3 1 --- --- 1 7 --- --- 8 --- --- --- 
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Table 6. Additional primary cancers and genetic testing results
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Additional 
primary 
cancer                           
  Breast 26 --- 1 1 2 --- 1 --- --- --- --- --- 
  Colon 14 1 --- --- 4 --- --- --- --- --- --- 1 
  Renal 5 --- --- --- --- --- --- --- --- --- --- 1 
  Sarcoma 8 --- 1 --- --- --- --- --- --- 4 --- --- 
  Thyroid 4 --- --- --- --- --- --- --- --- --- --- --- 
  Melanoma 4 --- --- --- 1 --- --- --- --- 1 --- --- 
  Ovarian 4 --- --- --- 1 --- 1 1 --- --- --- --- 
  Pancreatic 3 --- --- --- --- --- --- --- --- --- --- --- 
  Uterine 3 --- --- --- 2 1 --- --- --- --- --- --- 
  Prostate 2 --- --- --- --- --- --- --- --- --- --- --- 
  CNS 1 --- --- --- --- --- --- --- --- --- --- --- 
  Gastric 1 --- --- --- --- --- --- --- --- --- --- --- 
                            
Isolated 
PBT   35 3 4 --- 2 1 --- --- 1 3 1 --- 
19 
 
Family history  
Family history information was available for 821 relatives of 165 patients.  Among these 
patients, nearly all (n=157, 97%) reported a family history of some cancer and 55 (35%) reported a first-
degree relative with cancer.  The most common cancers in the family history were breast (220/821, 
27%), colorectal (73/821, 9%), and prostate (62/821, 8%). A family history of brain tumors was noted in 
30/165 (18%) patients, with 13 patients reporting a first-degree relative with a brain tumor. There was no 
difference in frequency of positive family history between patients that tested positive compared to those 
that tested negative or had a VUS.  Overall, patients with multiple primary cancers tended to have a 
stronger family history of cancer.  Among patients with family history information, 100% of the patients 
with 3 or more additional primaries reported a positive family history. 
Of patients for whom family history information was available, 22 of 165 (13%) received 
positive genetic test results. Sixteen of these 22 (73%) patients did not have a family history of brain 
tumors. Their test results revealed mutations in the genes: APC, BRCA2, CDKN2A, CHEK2, MLH1, 
MSH6, MUTYH, NF1, PMS2, SDHB, TP53, and VHL. The 6 individuals who did have a family history 
of brain tumors possessed mutations in the genes: APC, BRCA2, CHEK2, MUTYH, TP53, and VHL. 
Thus, having a family history of a brain tumor was not predictive of a positive genetic test result. Sixteen 
relatives were noted to previously have genetic testing with 7 yielding positive results in BRCA1 (5), 
PMS2, and BRCA2. The other 9 relatives were either negative or the outcome was not otherwise 
specified.  
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DISCUSSION.  
This is the first study, to our knowledge, to describe patient specific characteristics in a 
population of individuals undergoing genetic testing for a PBT. We investigated how these 
characteristics and family histories differ across mutation positive, negative, and VUS cohorts based on 
cancer panel genetic test results. We are laying the groundwork for development of future genetic testing 
criteria for a PBT, based off patient-specific characteristics, as well as aiding clinicians in better 
recognition of individuals requiring genetic testing. Typical indicators for other hereditary cancer 
syndromes can include, but are not limited to early age of diagnosis, family history, rare/specific 
pathology, and presence of additional primary cancers(25, 35-38).  
According to the American Brain Tumor Association, the median age of diagnosis for a PBT of 
any pathology is 59 years(23). In our population, however, the median age of diagnosis was significantly 
younger at 44 years (p<0.001). This indicates the population of patients undergoing genetic testing for a 
PBT are younger than typically observed. This is consistent with the National Society of Genetic 
Counselors (NSGC) and American College of Medical Genetics and Genomics (ACMG) joint practice 
guidelines(38) which suggest earlier age of brain tumor diagnosis can be utilized with other patient 
characteristics as a marker for referral to genetic counseling. In our cohort, there was no significant 
difference in age at diagnosis between the positive and negative cohorts, likely since 70% of our study 
population was under the age of 50 when diagnosed.  
Test result positive astrocytomas were found to be diagnosed at a significantly younger age than 
test result negative and VUS astrocytomas (p=0.021). Other studies have shown utility in pathology and 
younger age at diagnosis for PBTs. Pathmaban, et al reported an isolated meningioma or schwannoma 
diagnosed <25 yielded a positive test result 38% and 20% of the time, respectively(39). None of the 
patients in our cohort with an isolated meningioma or schwannoma were diagnosed at this early age. 
While no other pathology types noted age of diagnosis differences across test results, the astrocytoma 
findings suggest more research in this area is necessary. With a larger sample size, the potential role of 
pathology in association with earlier ages of diagnosis could be explored further.  
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Another indicator for referral to genetic counseling is tumor pathology, which can be used to 
create a differential diagnosis of various genetic syndromes. Typically, it is used in conjunction with 
another patient characteristic. We evaluated mutation positive individuals to see how their tumor 
pathology corresponded with associated syndromes. Out of the 84 patients with positive genetic testing 
results and available pathology, 17 (20%) had tumor pathology which was associated with their 
respective syndrome. The other 70 had pathology types which were not previously reported in 
individuals with that gene or syndrome. For example, there were 4 individuals with meningioma and 
MMR gene mutations. While the MMR genes can predispose a risk for PBTs, meningiomas are not the 
typical pathology noted in patients with Lynch syndrome or CMMRD. There have been case reports of 
patients with atypical PBT pathology and Lynch syndrome, including pituitary tumors(40) and choroid 
plexus carcinoma(41). Additionally, 3 individuals harbored mono-allelic MUTYH mutations, 2 of which 
had GBMs and 1 an oligodendroglioma. MUTYH carriers are not expected to be at increased risk to 
develop cancer and PBTs have not yet been observed as part of the MAP cancer spectrum. Case reports 
outline patients with astrocytoma(42) and high-grade glioma(43) in mono-allelic MUTYH mutation 
carriers. These findings suggest the spectrum of PBT pathology seen with these syndromes may be 
broader than we currently appreciate. It is also possible that some affected patients develop a PBT based 
on the general population risks unrelated to their genetic mutation.  
While tumor grade is not currently an indication for a genetic counseling referral, it may be 
important in risk assessment for a PBT. As expected based on the natural history of gliomas, our results 
indicated lower grade glial tumors were diagnosed at earlier ages than higher grade glial tumors. 
However, our results did not show an association between tumor grade and genetic testing results. 
Clinically, high grade PBTs are associated with some genetic conditions, such as CMMRD and LFS(5, 
20, 44). Our results suggest that while tumor grade is currently being used as an indicator for genetic 
counseling referral, more research is necessary to better understand the relationship with testing 
outcomes and the weight which should be placed on tumor grade in making genetic testing 
recommendations.  
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The NSCG/ACMG guidelines also suggest family history as an indicator for referral to genetic 
counseling. Family history information was available for 165 patients, 95% (157/165) of whom had a 
family history of cancer. Thus, positive family history appeared to be a referral and/or testing indication 
for this subset of patients. Our data echo the NSGC/ACMG recommendations and reflect the utility in a 
thorough pedigree evaluation.  A family history of PBTs was noted in 30 (18%) patients and 127 (80%) 
patients reported a family history of cancer aside from PBTs. There were 111 (67%) patients with a 
family history of breast cancer and 57 (35%) with colorectal cancer. Twenty-two patients (13%) had 
mutations in 12 genes: APC, BRCA2, CDKN2A, CHEK2, MLH1, MSH6, MUTYH, NF1, PMS2, SDHB, 
TP53, and VHL. Nine of 12 genes were related to breast or colorectal cancer. Of 8 individuals with 
family histories of only breast cancer, 5 (63%) possessed mutations in related genes (BRCA2 (4) and 
CHEK2). For 7 individuals with a family history of both breast and colorectal cancer, 5 (71%) had 
mutations in colorectal cancer genes (APC (2), MLH1, MSH6, PMS2) and 1/7 (14%) in a breast cancer 
gene (TP53). Although, these results represent a small subset of individuals, it suggests family history is 
a valuable risk assessment modality until specific PBT testing criteria are established. Family history 
could provide clues for the presence of a genetic etiology, as PBTs are associated with numerous 
hereditary cancer predisposition syndromes. Thus, non-PBT family history is as critical to evaluate as 
family history of brain tumors. 
Our data suggest PBTs can be the presenting feature in hereditary syndromes with a known risk 
for PBTs. Thirty-five of 104 (34%) individuals who tested positive had an isolated PBT and no 
additional primaries. These individuals possessed mutations in the genes: APC, ATM, BRCA1, BRCA2, 
CHEK2, MUTYH, NF1, PMS2, POLE, SMARCB1, TP53 and TSC2. Half of these genes, including—
APC, NF1, PMS2, SMARCB1, TP53, and TSC2—are associated with PBTs. For associated syndromes 
such as FAP, Lynch syndrome, or NF1, individuals would typically be expected to develop other cancers 
or have other recognizable, clinical features before a PBT. However, our data indicates individuals can 
present atypically. One case report details two brothers eventually found to have LFS; one presenting 
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with a glioblastoma and the other with multiple PBTs including a glioma and astrocytoma(45). Another 
case report reveals medulloblastoma as the presenting feature of FAP in an 11-year-old(42).  
For those genes with no known association with PBTs, we investigated if additional primaries 
could be an explanatory factor. The presence of multiple primaries in an individual could indicate an 
increased risk for a genetic syndrome. We evaluated the relationship between mutation positive test 
results and additional primaries. Half of patients harbored a mutation in a gene with a known association 
with PBTs. The remaining half returned results in genes with no known association to PBTs, including 
BRCA1/2, CHEK2, and POLE. A majority of these individuals (45/52, 87%) had mutations in genes 
predisposing a risk for breast and/or ovarian cancer, which was thought to be consistent with breast 
cancer being the most common additional primary cancer in this cohort, (226/654, 35%). However, 
individuals with breast cancer as an additional primary were largely not the ones testing positive for 
those mutations. Twenty-six of 45 (58%) individuals who possessed mutations in breast and/or ovarian 
cancer related genes did not have either cancer. For example, 8 of 14 (57%) individuals with a BRCA2 
mutation and 11 of 15 (73%) females with a CHEK2 mutation did not have breast or ovarian cancer.  
For genes with no known association with PBTs, it is challenging to delineate the relationship 
between the mutation and the PBT at this time. It is possible a subset poses a risk for PBTs and the 
spectrum of cancer types seen are broader than we currently understand. Case reports have described 
PBTs seen with MUTYH(43) and BRCA(46) mutation carriers, for example. However, since there was 
limited clinical and family history information available in our study, we are unable to comment on 
whether or not these results represent an incidental finding or if some of these genes do predispose a risk 
for PBTs. Ultimately, further research, particularly in an unbiased population, is necessary to for further 
evaluation. In the future, establishment of genetic testing criteria for PBTs will allow clinicians to 
appropriately identify patients for genetic testing. Harboring a mutation can alter management and 
screening of these individuals as they may be at risk for additional cancers.   
Limitations of this study include a biased sample population as these data were obtained from 
individuals in the PBT population who were selected to undergo genetic testing at a commercial 
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laboratory for a variety of reasons. Thus, our findings cannot be extrapolated to the general PBT 
population. Since patient information was obtained from the test requisition form, all clinical information 
is per provider report and not all fields were available for all patients. Thus, our cohorts differed for 
various comparisons, impacting the power of the associations we studied. Additionally, since clinical 
information was not available for all patients, variables such as whether or not an individual met various 
testing criteria or how the genetic test result fit with the patient’s clinical phenotype could not be 
evaluated.  
Further studies are needed to continue to understand the landscape of this population, especially 
on a larger scale. Primary brain tumors encompass a highly heterogeneous group of benign and 
malignant neoplasms; thus, large numbers are needed to adequately power these studies. Conducting 
research prospectively in a non-biased population will allow for further extrapolation. For example, since 
CHEK2 mutations were identified in 20% of our positive cohort, including patients with a variety of PBT 
pathologies and additional primary cancers, we feel additional studies are particularly needed in this 
population. Finally, while the NSGC/ACMG referral guidelines are beneficial resources, developing 
genetic testing criteria for PBTs is critical. Identification of a hereditary predisposition will allow for 
tailored treatment and risk-reducing measures for both the patient and at-risk family members. Until such 
criteria are established, future research could evaluate current testing practices and methods to make 
genetic counseling referral guidelines more robust. 
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CONCLUSION. 
This study evaluated individuals undergoing genetic testing for a PBT. Our data indicate that 
currently, despite the lack of genetic testing criteria for PBTs, testing is largely being ordered on 
individuals diagnosed under the age of 50 as well as those who have a positive cancer family history. 
Mutations were observed in 26 genes across 104 (13%) individuals. Half of the identified mutations were 
associated with a known PBT risk, while the remaining mutations were identified in genes with no 
known PBT risk. Approximately one-third of mutation positive individuals possessed an isolated PBT, 
suggesting PBTs can be the primary presenting cancer in hereditary syndromes with a known PBT risk. 
Evaluating the family history of all cancers was found to be a beneficial risk assessment modality, 
particularly until testing criteria are developed for PBTs. Further research is necessary to better 
understand the potential risks, benefits, and limitations of germline genetic testing in the PBT patient 
population.   
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